SIRT1 and cardiomyopathy: In summary, we found that administration of the small-molecule compound JQ-1 improved cardiac remodeling after MI by inhibiting ferroptosis through the NAMPT/SIRT1 pathway, indicating a novel potential strategy for the intervention of ferroptosis-related cardiomyopathy.